Stockreport

GSK obtains FDA approval for Exdensur in severe asthma [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF This means that the long-acting interleukin-5 (IL-5)-targeting monoclonal antibody (mAb) is now indicated for use in patients aged 12 years or older with severe asthma [Read more]